Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/160312
Title: | Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy |
Author: | Mandorfer, Mattias Kozbial, Karin Schwabl, Philipp Chromy, David Semmler, Georg Stättermayer, Albert F. Pinter, Matthias Hernández Gea, Virginia Fritzer-Szekere, Monika Steindl-Munda, Petra Trauner, Michael Peck-Radosavljevic, Markus García Pagán, Juan Carlos Ferenci, Peter Reiberger, Thomas |
Keywords: | Cirrosi hepàtica Hipertensió Interferó Hepatic cirrhosis Hypertension Interferon |
Issue Date: | 1-Mar-2020 |
Publisher: | John Wiley & Sons, Inc. |
Abstract: | BaCKgRoUND aND aIMS: Sustained virologic response (SVR) to interferon (IFN)-free therapies ameliorates portal hypertension (PH); however, it remains unclear whether a decrease in hepatic venous pressure gradient (HVPG) after cure of hepatitis C translates into a clinical benefit. We as- sessed the impact of pretreatment HVPG, changes in HVPG, and posttreatment HVPG on the development of hepatic decompensation in patients with PH who achieved SVR to IFN-free therapy. Moreover, we evaluated transient elastogra- phy (TE) and von Willebrand factor to platelet count ratio (VITRO) as noninvasive methods for monitoring the evolu- tion of PH. appRoaCH aND ReSUltS: The study comprised 90 patients with HVPG ≥ 6 mm Hg who underwent paired HVPG, TE, and VITRO assessments before (baseline [BL]) and after (follow-up [FU]) IFN-free therapy. FU HVPG but not BL HVPG predicted hepatic decompensation (per mm Hg, hazard ratio, 1.18; 95% confidence interval, 1.08- 1.28; P < 0.001). Patients with BL HVPG ≤ 9 mm Hg or patients who resolved clinically significant PH (CSPH) were protected from hepatic decompensation. In patients with CSPH, an HVPG decrease ≥ 10% was similarly protective (36 months, 2.5% vs. 40.5%; P < 0.001) but was observed in a substantially higher proportion of patients (60% vs. 24%; P < 0.001). Importantly, the performance of noninva- sive methods such as TE/VITRO for diagnosing an HVPG reduction ≥ 10% was inadequate for clinical use (area under the receiver operating characteristic curve [AUROC], < 0.8), emphasizing the need for HVPG measurements. However, TE/VITRO were able to rule in or rule out FU CSPH (AUROC, 0.86-0.92) in most patients, especially if assessed in a sequential manner. CoNClUSIoNS: Reassessment of HVPG after SVR im- proved prognostication in patients with pretreatment CSPH. An “immediate” HVPG decrease ≥ 10% was observed in the majority of these patients and was associated with a clinical benefit, as it prevented hepatic decompensation. These results support the use of HVPG as a surrogate endpoint for inter- ventions that lower portal pressure by decreasing intrahepatic resistance. |
Note: | Reproducció del document publicat a: https://doi.org/10.1002/hep.30885 |
It is part of: | Hepatology 2020, vol.71, num. 3, p. 1023-1036 |
URI: | http://hdl.handle.net/2445/160312 |
Related resource: | https://doi.org/10.1002/hep.30885 |
ISSN: | 1527-3350 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_5900106_16545960.pdf | 623.21 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License